Project description:To investigate the genome-wide binding pattern of Fezf2, we performed ChIP-seq analysis for Fezf2. ChIP-seq of transcription factor in mTECs is difficult because of small number of mTECs or difficulty in gaining ChIP grade antibodies. Then, we generated Fezf2-3Flag knock in mice and performed ChIP-seq analysis by using anti-Flag antibody.
Project description:To integrate the epigenomic landscapes of chromatin accessibility regulated by Chd4 and Fezf2, we performed the assay for transposase-accessible chromatin using sequencing (ATAC-seq) analysis of mTECs from wild type (WT), Chd4 cKO and Fezf2 cKO mTECs.
Project description:Fezf2 is highly and specifically expressed in mTECs in mouse thymus and Fezf2 deficiency (Fezf2 KO) in the thymus leads to autoimmunity. However, it is unclear how Fezf2 contributes to thymic gene expression. We collected WT and Fezf2 KO mTECs by FACS, and performed microarrays to determine genes regulated by Fezf2. mTECs were subjected to RNA extraction (from WT or Fezf2 KO mTECs) and hybridization on Affymetrix microarrays.
Project description:To gain insights into the difference in transcriptional programs regulated by Fezf2, Aire and Chd4, we performed RNA sequencing (RNA-seq) of mTECs from Fezf2-deficient, Aire-deficient and Chd4-deficient mice.
Project description:Fezf2 is highly and specifically expressed in mTECs in mouse thymus and Fezf2 deficiency (Fezf2 KO) in the thymus leads to autoimmunity. However, it is unclear how Fezf2 contributes to thymic gene expression. We collected WT and Fezf2 KO mTECs by FACS, and performed microarrays to determine genes regulated by Fezf2.
Project description:We performed ChIP-Seq against histones H3K4me3 and H3K27me3 in medullary thymic epithelial cells (mTECs) of wild-type mice to analysis bivalent epigenetic modifications.
Project description:ChIP sequencing of Ehf, Fezf2, Elf3 and Klf4 was performed on medullary thymic epithelial cells to analyze the role of Ehf-, Fezf2-, Elf3- and Klf4-dependent gene regulation in mTECs.
Project description:Estrogen Receptor alpha (ERα) is a key driver of most breast cancers, and it is the target of endocrine therapies used in the clinic to treat women with ERα positive (ER+) breast cancer. The two methods ChIP-seq (chromatin immunoprecipitation coupled with deep sequencing) and RIME (Rapid Immunoprecipitation of Endogenous Proteins) have greatly improved our understanding of ERα function during breast cancer progression and in response to anti-estrogens. A critical component of both ChIP-seq and RIME protocols is the antibody that is used to pull down the bait protein. To date, most of the ChIP-seq and RIME experiments for the study of ERα have been performed using the sc-543 antibody from Santa Cruz Biotechnology. However, this antibody has been discontinued, thereby severely impacting the study of ERα in normal physiology as well as diseases such as breast cancer and ovarian cancer. Here, we compare the sc-543 antibody with other commercially available antibodies, and we show that 06-935 (EMD Millipore) and ab3575 (Abcam) antibodies can successfully replace the sc-543 antibody for ChIP-seq and RIME experiments.
